Emany Sravan Kumar 4

What Happened

• Emany Sravan Kumar, a director of Kyverna Therapeutics (KYTX), received equity awards on 2026-02-24. The Form 4 reports (1) 11,006 restricted stock units (RSUs) granted at $0 and (2) 42,945 derivative shares (an option or option-like award) granted at $0. Combined, the awards cover 53,951 shares; no cash was paid at grant.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (filed within typical two-business-day window).
• Prices and values: both grants reported at $0 acquisition price (standard for equity compensation grants); total immediate cash value not reported.
• Vesting: the 11,006 RSUs vest 1/3 on each anniversary of the grant (footnote F1). The 42,945 derivative shares vest monthly at 1/36th per month (footnote F2).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Transaction code: A (award/grant). No sale or exercise reported here.

Context

• These are compensation awards tied to continued service; they typically vest over time and are not immediately sellable until vested. The derivative award appears to be an option-style grant with monthly vesting over three years. This is a grant (not a market purchase or sale) and should be viewed as compensation rather than an immediate vote of market confidence.